Raymond James sets USD 420.00 target for Alnylam Pharmaceuticals stock

Published on 10/24/2026 at 20:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alnylam reports results October 29, 2026. Alnylam Pharmaceuticals stock costs EUR 200.40 on October 23, 2026 versus Tradegate close.

Analyst target and reporting date

Raymond James maintained a Strong Buy rating and a USD 420.00 target on October 23, 2026.
Alnylam scheduled third-quarter results for October 29, 2026.
Alnylam Pharmaceuticals stock was quoted at EUR 200.40 on Tradegate on October 23, 2026, unchanged versus the Tradegate close.
The company had a USD 30.0 billion market capitalization as of October 23, 2026.

Alnylam Pharmaceuticals, US02043Q1076, Illustration mit AI erstellt.

Alnylam Pharmaceuticals stock is paired with a USD 420.00 price target and a Strong Buy rating from Raymond James, according to Investing.com on October 23, 2026. Tradegate quoted the stock at EUR 200.40 on October 23, 2026 at 9:44 p.m. CEST, unchanged versus the Tradegate close.

Raymond James sees room above USD 420.00

Raymond James reiterated its Strong Buy rating and USD 420.00 target after Alnylam presented interim brezosiran information, the Investing.com report said. Against the Nasdaq price of USD 224.03 on October 23, 2026, the target lies 87.47 percent above the stock price.

Stock remains below its yearly high

Alnylam's Nasdaq price stood at USD 224.03 on October 23, 2026, while its 52-week range ran from USD 197.81 to USD 485.36. The stock therefore stood 53.75 percent below its 52-week high.

Alnylam's market capitalization was USD 30.0 billion as of October 23, 2026. The price to earnings ratio was 37.84 on the same date, placing valuation in the context of a stock trading well above its yearly low but below its yearly high.

Results are scheduled for October 29

Alnylam's investor calendar lists its third-quarter 2026 earnings conference call for October 29, 2026 at 8:30 a.m. EDT, according to Alnylam Pharmaceuticals. The calendar also lists an RNAi roundtable on October 26, 2026 at 10:00 a.m. EDT.

What does the target imply?

The USD 420.00 target would require an 87.47 percent gain from the USD 224.03 Nasdaq price. The gap leaves the upcoming October 29 results as the next dated test for the valuation case.